Immunic, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IMUX research report →
Range $3 – $45
Price Chart
About the company
Immunic, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to pioneering selective oral immunotherapies for a range of chronic inflammatory and autoimmune conditions. Its primary investigational compound, IMU-838, has advanced to Phase 2 clinical trials, targeting relapsing-remitting multiple sclerosis (RRMS), inflammatory bowel disease (IBD), various other chronic inflammatory and autoimmune disorders, and also coronavirus disease.
- CEO
- Erik Lundgren
- IPO
- 2014
- Employees
- 100
- HQ
- New York City, NY, US
Get TickerSpark's AI analysis on IMUX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $95.37M
- P/E
- -1.65
- Fwd P/E
- 3.72
- PEG
- -0.02
- P/S
- 0.00
- P/B
- 3.03
- EV/EBITDA
- 0.24
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -136.26%
- ROIC
- -128.67%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-103,228,000
- Net Income
- $-97,172,000+3.3%
- EPS
- $-6.24+37.8%
- OCF Growth
- -1.2%
- FCF Growth
- -1.1%
- 52W High
- $17.43
- 52W Low
- $5.06
- 50D MA
- $8.29
- 200D MA
- $11.58
- Beta
- 1.48
- RSI (14)
- 39
- Avg Volume
- 341.13K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Immunic said its MS program kept advancing in Q3, with ENSURE passing an IDMC futility check and CALLIPER still on track for a topline readout in April 2025, while cash of $59.1 million is expected to fund operations into Q3 2025.· November 7, 2024
- ENSURE’s interim analysis was favorable: the IDMC said the Phase 3 trials are not futile and should continue as planned.
- CALLIPER topline data in progressive MS is expected in April 2025, and management said the readout should be detailed across subforms and key biomarkers.
- Management continued to emphasize vidofludimus calcium’s dual mechanism, oral convenience, and possible differentiation in both relapsing and progressive MS.
- Immunic ended Q3 with $59.1 million in cash and cash equivalents, which it expects to fund operations into the third quarter of 2025.
- The company said it is still in ongoing partnering discussions for vidofludimus calcium and believes interest has increased after recent BTK inhibitor setbacks.
Immunic did not report product revenue on the call. Q3 2024 net loss was approximately $24.4 million, or $0.24 per basic and diluted share, versus a net loss of approximately $22.8 million, or $0.51 per share, in Q3 2023. Nine-month 2024 net loss was approximately $75.3 million, or $0.75 per share, versus approximately $72 million, or $1.63 per share, in the prior-year period. R&D expense was $21.4 million in Q3 2024 versus $19.8 million a year ago, and $58.4 million for the first nine months of 2024 versus $63.9 million last year. G&A expense was $4.4 million in Q3 2024 versus $3.8 million a year ago, and $14 million for nine months versus $11.9 million. Cash and cash equivalents were $59.1 million at September 30, 2024, which management said should fund operations into Q3 2025. Guidance-wise, the company expects CALLIPER topline data in April 2025, expects to complete the first ENSURE trial in Q2 2026 and the second in 2H 2026, and is preparing for Phase 2 testing of IMU-856 while exploring separate funding options for that asset.
Daniel Vitt framed the quarter around clinical and organizational progress, including added leadership, a strengthened board, and higher visibility for vidofludimus calcium at the MS R&D day and ECTRIMS. He repeatedly emphasized the drug’s dual mode of action, calling out neuroprotective Nurr1 activation plus anti-inflammatory DHODH inhibition, and said the company believes it could serve both relapsing and progressive MS. His tone was optimistic but still data-dependent, with emphasis on upcoming milestones rather than commercialization claims.
Glenn Whaley focused on the balance sheet and quarterly spending trends. He said cash and cash equivalents were $59.1 million at quarter-end and expected to fund operations into the third quarter of 2025. He also broke down Q3 2024 R&D expense of $21.4 million, G&A expense of $4.4 million, interest income of $0.8 million, other income of $600,000, and a Q3 net loss of $24.4 million; for nine months, R&D was $58.4 million, G&A was $14 million, interest income was $3 million, other income was negative $1.1 million, and net loss was $75.3 million. He attributed higher R&D in the quarter mainly to external clinical trial spending, partly offset by deprioritization of izumerogant, and noted the $4.8 million non-cash charge from tranche rights related to the January 2024 private placement.
Analysts focused heavily on CALLIPER: management said the April 2025 readout should include detailed data across the overall population and subforms, including confirmed disability worsening, NfL, GFAB, and brain atrophy. On post-COVID fatigue data, Daniel Vitt said the investigator-sponsored study is not under Immunic’s control, so he could not guide on timing, but he said the overlap of fatigue and EBV biology could be scientifically meaningful; he also said any post-COVID subgroup analysis in ENSURE or CALLIPER is not predefined, though it could be extracted later if relevant. On efficacy expectations in CALLIPER, Vitt said there is no hard hazard-ratio bar, but he suggested KOLs viewed about a 15% disability-protection benefit as meaningful and 20% as a clear signal, and he said accelerated approval could be discussed depending on the data. When asked about partnering, Jason Tardio said Immunic is talking to nearly every company with MS or neuroscience interest, and that interest has risen after recent BTK inhibitor failures, but he gave no specifics.
The bullish case from this call is that Immunic has multiple near- to medium-term catalysts in a field with clear unmet need. ENSURE cleared an important futility hurdle, CALLIPER is approaching a detailed April 2025 readout, and management believes vidofludimus calcium could differentiate on efficacy, safety, oral dosing, and potential benefit in both relapsing and progressive MS. The company also said partnering interest is significant and may have increased recently.
The main risks are that the company remains pre-commercial, with no revenue and a cash runway only into Q3 2025. Management repeatedly noted that CALLIPER is blinded and no conclusions can be drawn yet, while accelerated approval or partnership outcomes remain uncertain and data-dependent. The post-COVID study timing is also outside Immunic’s control, and IMU-856 still needs more clinical development and separate funding options are still being explored.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 88.0%
- Shares Outstanding
- 13.64M
- Float Shares
- 12.01M
of shares held by institutions
61 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 5.02M | ▲ 675.23K |
| Aberdeen Group PLC | 1.09M | ▲ 266.03K |
| Bvf Inc/Il | 765.29K | 0 |
| Morgan Stanley | 704.24K | ▲ 680.50K |
| Seven Fleet Capital Management LP | 687.24K | ▲ 687.24K |
| Millennium Management LLC | 681.02K | ▼ 59.32K |
| Avidity Partners Management LP | 669.94K | 0 |
| Braidwell LP | 645.11K | ▲ 100 |
| Laurion Capital Management LP | 610.33K | 0 |
| Vanguard Capital Management LLC | 571.56K | 0 |
| Orbimed Advisors LLC | 475.80K | ▲ 475.80K |
| Woodline Partners LP | 472.00K | ▲ 472 |
Held by 37 ETFs
Biggest fund positions in IMUX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 16, 26 | Nagel Robert Thorvald | other | 25,370 |
| Sep 16, 26 | BVF PARTNERS L P/IL | other | 25,370 |
| Aug 6, 26 | Ridloff Elena | other | 50,740 |
| Aug 6, 26 | Ridloff Elena | other | 0 |
| Jul 5, 26 | Skerjanec Simona | other | 25,370 |
| Jul 5, 26 | Rudick Richard Alan | other | 25,370 |
| Jul 5, 26 | PHILLIPS BARCLAY A | other | 25,370 |
| Jul 5, 26 | Neermann Joerg | other | 25,370 |
| Jul 5, 26 | Congleton Jon | other | 25,370 |
| Jun 29, 26 | Congleton Jon | other | 50,740 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our IMUX coverage
Recent articles, reports, and earnings notes.
No research on IMUX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate IMUX report →Immunic, Inc. Reports Third Quarter 2026 Financial Results and Provides Corporate Update
prnewswire.com · Nov 13
Immunic, Inc. (IMUX) Progressive Multiple Sclerosis R&D Day: Vidofludimus Calcium Development Transcript
seekingalpha.com · Nov 9
Immunic Plans Phase 3 Progressive MS Trial After Mixed Phase 2 Results
marketbeat.com · Nov 6
Immunic to Participate in Investor Conferences in November
prnewswire.com · Nov 2
Immunic to Host Virtual Progressive Multiple Sclerosis R&D Day on November 5, 2026
prnewswire.com · Oct 29
New Strong Buy Stocks for October 22nd
zacks.com · Oct 22
Immunic Presents New Clinical, Biomarker, and Preclinical Data for Vidofludimus Calcium in Four Poster Presentations at MSToronto2026 - the 10th Joint ACTRIMS-ECTRIMS Meeting
prnewswire.com · Oct 21
Immunic adds new Chief People Officer ahead of Phase 3 readout
proactiveinvestors.com · Oct 19
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.